Experienced in Multiple Carboxylase Deficiency

Dr. Suzanne R. Fanning

Hematology Oncology | Hematology | Oncology
Prisma Health University Medical Group
701 Grove Rd, 
Greenville, SC 
Accepting New Patients
Offers Telehealth
Experienced in Multiple Carboxylase Deficiency
Prisma Health University Medical Group
701 Grove Rd, 
Greenville, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suzanne Fanning is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Fanning is rated as an Experienced provider by MediFind in the treatment of Multiple Carboxylase Deficiency. Her top areas of expertise are Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fanning is currently accepting new patients.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SC
Hospital Affiliations
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Hillcrest Hospital
Prisma Health Oconee Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

PRISMA HEALTH UNIVERSITY MEDICAL GROUP
701 Grove Rd, Greenville, SC 29605
Other Locations
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
65 International Dr, Greenville, SC 29615
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
900 W Faris Rd, Greenville, SC 29605
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
210 Freeman Farm Rd, Duncan, SC 29334

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Biological
Study Drug: Lisocabtagene maraleucel
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

14 Total Publications

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Journal: American journal of cancer research
Published: May 19, 2025
Similar Doctors
Distinguished in Multiple Carboxylase Deficiency
Dr. Pramod R. Ganta
Hematology Oncology | Hospital Medicine | Hematology
Distinguished in Multiple Carboxylase Deficiency
Dr. Pramod R. Ganta
Hematology Oncology | Hospital Medicine | Hematology
3617 Hwy 81 N, 
Anderson, SC 
 (24.3 miles away)
864-540-8430
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Pramod Ganta is a Hematologist Oncology specialist and a Hospital Medicine provider in Anderson, South Carolina. Dr. Ganta is rated as an Advanced provider by MediFind in the treatment of Multiple Carboxylase Deficiency. His top areas of expertise are Folate Deficiency, Multiple Carboxylase Deficiency, Vitamin B12 Deficiency Anemia, and Subacute Combined Degeneration. Dr. Ganta is currently accepting new patients.

Distinguished in Multiple Carboxylase Deficiency
Dr. Matthew M. Rees
Hematology Oncology | Hematology | Oncology
Distinguished in Multiple Carboxylase Deficiency
Dr. Matthew M. Rees
Hematology Oncology | Hematology | Oncology
201 E Grover St, 
Shelby, NC 
 (59.7 miles away)
980-487-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Rees is a Hematologist Oncology specialist and a Hematologist in Shelby, North Carolina. Dr. Rees is rated as a Distinguished provider by MediFind in the treatment of Multiple Carboxylase Deficiency. His top areas of expertise are Myelodysplastic Syndrome (MDS), Colorectal Cancer, Lynch Syndrome, and Lung Adenocarcinoma. Dr. Rees is currently accepting new patients.

Distinguished in Multiple Carboxylase Deficiency
Dr. Tondre T. Buck
Hematology Oncology | Oncology | Hematology
Distinguished in Multiple Carboxylase Deficiency
Dr. Tondre T. Buck
Hematology Oncology | Oncology | Hematology

Spartanburg Medical Center

101 E Wood St, 
Spartanburg, SC 
 (28.6 miles away)
864-560-6193
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tondre Buck is a Hematologist Oncology specialist and an Oncologist in Spartanburg, South Carolina. Dr. Buck is rated as a Distinguished provider by MediFind in the treatment of Multiple Carboxylase Deficiency. His top areas of expertise are Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Buck is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fanning's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 101 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile